These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 22118704)

  • 1. Optimal management of type 2 diabetes: the evidence.
    Colagiuri S
    Diabetes Obes Metab; 2012 Jan; 14 Suppl 1():3-8. PubMed ID: 22118704
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Which patients should be evaluated for blood glucose variability?
    Candido R
    Diabetes Obes Metab; 2013 Sep; 15 Suppl 2():9-12. PubMed ID: 24034514
    [TBL] [Abstract][Full Text] [Related]  

  • 3. HbA1c targets in type 2 diabetes: guidelines and evidence.
    Drug Ther Bull; 2013 Apr; 51(4):42-5. PubMed ID: 23557845
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Type 2 diabetes and HbA1c targets.
    Prescrire Int; 2008 Dec; 17(98):254. PubMed ID: 19425272
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Relationship of glycated haemoglobin and reported hypoglycaemia to cardiovascular outcomes in patients with type 2 diabetes and recent acute coronary syndrome events: The EXAMINE trial.
    Heller SR; Bergenstal RM; White WB; Kupfer S; Bakris GL; Cushman WC; Mehta CR; Nissen SE; Wilson CA; Zannad F; Liu Y; Gourlie NM; Cannon CP;
    Diabetes Obes Metab; 2017 May; 19(5):664-671. PubMed ID: 28058763
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Delays in treatment intensification with oral antidiabetic drugs and risk of microvascular and macrovascular events in patients with poor glycaemic control: An individual patient simulation study.
    Folse HJ; Mukherjee J; Sheehan JJ; Ward AJ; Pelkey RL; Dinh TA; Qin L; Kim J
    Diabetes Obes Metab; 2017 Jul; 19(7):1006-1013. PubMed ID: 28211604
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hypoglycaemia? Not guilty! Decreased HbA1c? Not guilty!
    Roussel R; Cosson E
    Diabetes Metab; 2010 Feb; 36(1):86-7. PubMed ID: 19716740
    [No Abstract]   [Full Text] [Related]  

  • 8. Higher type 2 diabetes-related mortality when HbA1c levels are too low.
    Prescrire Int; 2008 Oct; 17(97):213. PubMed ID: 19536943
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Does aggressive glycemic control benefit macrovascular and microvascular disease in type 2 diabetes? Insights from ACCORD, ADVANCE, and VADT.
    Terry T; Raravikar K; Chokrungvaranon N; Reaven PD
    Curr Cardiol Rep; 2012 Feb; 14(1):79-88. PubMed ID: 22160862
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Individualizing glycemic targets in type 2 diabetes mellitus: implications of recent clinical trials.
    Ismail-Beigi F; Moghissi E; Tiktin M; Hirsch IB; Inzucchi SE; Genuth S
    Ann Intern Med; 2011 Apr; 154(8):554-9. PubMed ID: 21502652
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of glucose-lowering agents on vascular outcomes in type 2 diabetes: a critical reappraisal.
    Scheen AJ; Charbonnel B
    Diabetes Metab; 2014 Jun; 40(3):176-85. PubMed ID: 24792220
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Glucose control in diabetes: which target level to aim for?
    Laakso M; Cederberg H
    J Intern Med; 2012 Jul; 272(1):1-12. PubMed ID: 22321169
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Individualised treatment targets in patients with type-2 diabetes and hypertension.
    Schmieder RE; Tschöpe D; Koch C; Ouarrak T; Gitt AK;
    Cardiovasc Diabetol; 2018 Jan; 17(1):18. PubMed ID: 29357854
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Glycaemic control: a balancing act or a different approach?
    Fava S
    Curr Diabetes Rev; 2014 Mar; 10(2):124-30. PubMed ID: 24745817
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Management of hyperglycaemia in type 2 diabetes: a patient-centered approach].
    Scheen AJ; Mathieu C
    Rev Med Liege; 2012 Dec; 67(12):623-31. PubMed ID: 23342872
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of insulin lispro protamine suspension versus insulin glargine once daily added to oral antihyperglycaemic medications and exenatide in type 2 diabetes: a prospective randomized open-label trial.
    Arakaki RF; Blevins TC; Wise JK; Liljenquist DR; Jiang HH; Jacobson JG; Martin SA; Jackson JA
    Diabetes Obes Metab; 2014 Jun; 16(6):510-8. PubMed ID: 24298995
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Type 2 diabetes: target HbA1c of about 7%.
    Prescrire Int; 2009 Aug; 18(102):177. PubMed ID: 19746575
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Individualised treatment targets for elderly patients with type 2 diabetes using vildagliptin add-on or lone therapy (INTERVAL): a 24 week, randomised, double-blind, placebo-controlled study.
    Strain WD; Lukashevich V; Kothny W; Hoellinger MJ; Paldánius PM
    Lancet; 2013 Aug; 382(9890):409-416. PubMed ID: 23706759
    [TBL] [Abstract][Full Text] [Related]  

  • 19. To What Target Hemoglobin A1c Level Would You Treat This Patient With Type 2 Diabetes?: Grand Rounds Discussion From Beth Israel Deaconess Medical Center.
    Smetana GW; Nathan DM; Dugdale DC; Burns RB
    Ann Intern Med; 2019 Oct; 171(7):505-513. PubMed ID: 31569249
    [TBL] [Abstract][Full Text] [Related]  

  • 20. (Ultra-)long-acting insulin analogues versus NPH insulin (human isophane insulin) for adults with type 2 diabetes mellitus.
    Semlitsch T; Engler J; Siebenhofer A; Jeitler K; Berghold A; Horvath K
    Cochrane Database Syst Rev; 2020 Nov; 11(11):CD005613. PubMed ID: 33166419
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.